Baseline demographics
| Placebo | Golimumab 50 mg | Golimumab 100 mg | Combined golimumab | |
|---|---|---|---|---|
| Overall population | ||||
| n | 113 | 146 | 146 | 292 |
| Age (years) | 47 (40, 54) | 44 (38, 54) | 50 (39, 56) | 47 (38.5, 55) |
| Weight (kg) | 86.3 (70, 96.8) | 80.7 (69.3, 94.3) | 84.6 (71.6, 99.2) | 82.9 (70.2,96.9) |
| Sex (% male) | 61% | 61% | 59% | 60% |
| Race (% Caucasian) | 97% | 97% | 97% | 97% |
| CRP (µg/ml) | 0.6 (0.3, 1.3) | 0.6 (0.3, 1.6) | 0.6 (0.3, 1.7) | 0.6 (0.3, 1.6) |
| Methotrexate use (% yes) | 48% | 49% | 47% | 48% |
| Swollen joint count | 13.4±9.8 | 14.1±11.4 | 12±8.5 | 13±10.1 |
| Tender joint count | 21.9±14.7 | 24±17.1 | 22.5±15.7 | 23.3±16.4 |
| PASI | 6.52±6.83 | 7.85±8.14 | 8.76±9.13 | 7.81±8.22 |
| Biomarker substudy population | ||||
| N | 26 | 39 | 35 | 74 |
| Age (years) | 42.5 (36, 53.5) | 47 (41, 52.5) | 52 (43, 56.5) | 48.5 (42, 55.8) |
| Weight (kg) | 87.3 (71.2, 96.8) | 88 (79.2, 103.5) | 95.4 (76.4, 104.7) | 90 (79, 104) |
| Sex (% male) | 54% | 67% | 60% | 64% |
| Race (% Caucasian) | 96% | 92% | 94% | 93% |
| CRP (µg/ml) | 0.6 (0.3, 1.3) | 0.6 (0.3, 1.2) | 0.9 (0.4, 2.1) | 0.6 (0.3, 1.4) |
| Methotrexate usage (% yes) | 38% | 33% | 37% | 35% |
| Swollen joint count | 11.8±8.7 | 13±7.4 | 10.3±4.9 | 11.7±6.4 |
| Tender joint count | 20.7±12.5 | 21.1±13 | 21±10.5 | 21.1±11.8 |
| PASI | 5.67±4.26 | 7.77±6.38 | 9.80±9.20 | 7.93±7.20 |
Data are presented as median (IQR) or mean±SD unless otherwise noted.
CRP, C-reactive protein; PASI, psoriasis area and severity index.